Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27616265 | 0.84 | JAK3 (0.36) | POLBJAK3SLC8A1LMNAALDH1A1 | |
| SCHEMBL6079582 | 0.81 | TSHR (0.40) | PDE4BJAK3SLC8A1 | |
| SCHEMBL27562892 | 0.78 | JAK3 (0.36) | POLBJAK3SLC8A1LMNAALDH1A1 | |
| SCHEMBL13446383 | 0.77 | POLB (0.54) | POLBPDE4BLMNAALDH1A1NPC1 | |
| SCHEMBL17327601 | 0.77 | POLB (0.54) | POLBPDE4BLMNAGRM5GRM7 | |
| SCHEMBL20331842 | 0.77 | POLB (0.54) | POLBPDE4BLMNAALDH1A1NPC1 | |
| SCHEMBL12522309 | 0.77 | POLB (0.54) | POLBPDE4BLMNAGRM5GRM7 | |
| SCHEMBL12521642 | 0.77 | POLB (0.54) | POLBPDE4BLMNAGRM5GRM7 | |
| SCHEMBL15765934 | 0.77 | EPHX1 (0.48) | ALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL17718762 | 0.77 | JAK3 (0.35) | POLBJAK3LMNAALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842699-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-RE41783-E1 | Immunosuppressants; organ transplant; CP 690550 which is 3-(4-Methyl-3-(methyl-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-amino)-piperidin-1-yl)-3-oxo-propionitrile; inhibitors of the enzyme protein kinases such as Janus Kinase 3 | PFIZER INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100035903-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | BLUMENKOPF TODD A | 2010-02-11 | — | — | US | disclosed |
| US-7601727-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2008029237-A2 | COMBINATION THERAPIES FOR RHEUMATOID ARTHRITIS | PFIZER PRODUCTS INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070292430-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | BLUMENKOPF TODD A | 2007-12-20 | — | — | US | disclosed |
| EP-1382339-B1 | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives | PFIZER PROD INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7265221-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7250420-B2 | Method of treatment of transplant rejection | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060241131-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2006-10-26 | — | — | US | disclosed |
| US-20050159433-A1 | Method treatment of transplant rejection | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
| US-20050113395-A1 | Method of treatment of atherosclerosis | PFIZER INC | 2005-05-26 | — | — | US | disclosed |
| US-20040116449-A1 | Method of treatment of transplant rejection | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20040053947-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1382339-A1 | Compositions containing pyrrolo [2,3-d] pyrimidine derivatives | Pfizer Products Inc. (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1235830-B1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS | PFIZER PROD INC (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6627754-B2 | Immunosuppressants; organ transplant; CP 690550 which is 3-(4-Methyl-3-(methyl-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-amino)-piperidin-1-yl)-3-oxo-propionitrile | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1235830-A2 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20010053782-A1 | Immunosuppressants; organ transplant | BLUMENKOPF TODD A (US) | 2001-12-20 | — | — | US | disclosed |
| WO-2001042246-A2 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035903-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | JAK3, JAK1, PDXK | POLB 325/4885PDE4B 2600/4885JAK3 1/4885 |
| US-20040053947-A1 | Pyrrolo[2,3-D]pyrimidine compounds | JAK1, JAK3, TPMT | POLB 254/4885PDE4B 3241/4885JAK3 2/4885 |
| US-20070292430-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | JAK3, JAK1, PDXK | POLB 325/4885PDE4B 2600/4885JAK3 1/4885 |
| US-20050159433-A1 | Method treatment of transplant rejection | ARG1, TST, CD74 | POLB 4614/4885PDE4B 2053/4885JAK3 1530/4885 |
| US-20060241131-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK3, JAK1, PDXK | POLB 325/4885PDE4B 2600/4885JAK3 1/4885 |
| US-20010053782-A1 | Immunosuppressants; organ transplant | JAK1, JAK3, TPMT | POLB 2781/4885PDE4B 4306/4885JAK3 2/4885 |
| US-20050113395-A1 | Method of treatment of atherosclerosis | LDLR, MSR1, NR1H2 | POLB 1685/4885PDE4B 1184/4885JAK3 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.